Product
7 Interestana reports mention Keytruda, newest first. Each is summarised from the original reporting and links back to its publisher.
Moderna's personalized mRNA cancer vaccine has shown promising results in a clinical trial, successfully preventing the recurrence of melanoma in patients. The study, published online on August 20, 2026, in Nature, indicates that the vaccine could be a significant advancement…
Merck and Moderna announced on December 13, 2023, that their investigational mRNA cancer vaccine, in combination with Merck's immunotherapy Keytruda (pembrolizumab), demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) for patients with stage III or IV…
Moderna is placing significant strategic emphasis on its messenger RNA (mRNA) technology, the same platform that underpinned its highly successful COVID-19 vaccines, to pioneer a new generation of cancer treatments.
Moderna and Merck announced on June 5, 2024, that their investigational mRNA-based cancer vaccine, Intisemran (mRNA-4157/V940), significantly reduced the risk of melanoma recurrence and spread in patients with high-risk stage III/IV melanoma.
Pharmaceutical companies Moderna and Merck announced on Wednesday that their experimental mRNA-based cancer vaccine, designed to target a patient's specific tumor mutations, demonstrated efficacy in a Phase 3 clinical trial for melanoma patients.
Moderna and Merck announced promising results from a late-stage clinical trial for a personalized mRNA vaccine designed to prevent the recurrence of melanoma, the deadliest form of skin cancer. The trial, which involved a substantial number of participants, demonstrated…
Moderna's experimental personalized cancer vaccine, mRNA-4157/V940, has demonstrated early encouraging results in a Phase 2b clinical trial, offering a potential new avenue for cancer treatment and a significant opportunity for the biotechnology company.